BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 339 filers reported holding BIO-TECHNE CORP in Q2 2018. The put-call ratio across all filers is 3.84 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,434 | -18.1% | 50,448 | -1.4% | 0.01% | -20.0% |
| Q2 2023 | $4,191 | +4.6% | 51,143 | -5.3% | 0.01% | 0.0% |
| Q1 2023 | $4,008 | -10.8% | 53,989 | -0.1% | 0.01% | -16.7% |
| Q4 2022 | $4,495 | -99.9% | 54,061 | +187.1% | 0.01% | -20.0% |
| Q3 2022 | $5,344,000 | -18.6% | 18,832 | -0.5% | 0.02% | -11.8% |
| Q2 2022 | $6,562,000 | -31.5% | 18,918 | -10.3% | 0.02% | -15.0% |
| Q1 2022 | $9,583,000 | -14.9% | 21,086 | -3.3% | 0.02% | -13.0% |
| Q4 2021 | $11,264,000 | +7.4% | 21,811 | +1.4% | 0.02% | -4.2% |
| Q3 2021 | $10,487,000 | -7.4% | 21,507 | -14.6% | 0.02% | -7.7% |
| Q2 2021 | $11,322,000 | +94.6% | 25,188 | +64.9% | 0.03% | +85.7% |
| Q1 2021 | $5,819,000 | +12.3% | 15,279 | -6.4% | 0.01% | +40.0% |
| Q4 2020 | $5,182,000 | +14.4% | 16,326 | -10.8% | 0.01% | 0.0% |
| Q3 2020 | $4,529,000 | -10.7% | 18,296 | -4.9% | 0.01% | -16.7% |
| Q2 2020 | $5,074,000 | +34.8% | 19,232 | -3.1% | 0.01% | +20.0% |
| Q1 2020 | $3,763,000 | -6.0% | 19,848 | +8.1% | 0.01% | +11.1% |
| Q4 2019 | $4,002,000 | -14.1% | 18,359 | -17.8% | 0.01% | -18.2% |
| Q2 2019 | $4,657,000 | +2.2% | 22,341 | -2.7% | 0.01% | -8.3% |
| Q1 2019 | $4,556,000 | +46.4% | 22,958 | -0.9% | 0.01% | +33.3% |
| Q4 2018 | $3,113,000 | -29.7% | 23,173 | +6.8% | 0.01% | -18.2% |
| Q3 2018 | $4,428,000 | +38.0% | 21,689 | +0.0% | 0.01% | +37.5% |
| Q2 2018 | $3,208,000 | -6.0% | 21,686 | -4.0% | 0.01% | 0.0% |
| Q1 2018 | $3,413,000 | +20.6% | 22,599 | +3.4% | 0.01% | +14.3% |
| Q4 2017 | $2,831,000 | +4.2% | 21,852 | -3.1% | 0.01% | 0.0% |
| Q3 2017 | $2,717,000 | +3.9% | 22,552 | +1.3% | 0.01% | 0.0% |
| Q2 2017 | $2,615,000 | +16.4% | 22,259 | +0.6% | 0.01% | +16.7% |
| Q1 2017 | $2,247,000 | +2.5% | 22,118 | +3.8% | 0.01% | 0.0% |
| Q4 2016 | $2,193,000 | -54.0% | 21,307 | -51.1% | 0.01% | -14.3% |
| Q3 2016 | $4,766,000 | +98.1% | 43,538 | +104.1% | 0.01% | 0.0% |
| Q2 2016 | $2,406,000 | +577.7% | 21,329 | +467.6% | 0.01% | +600.0% |
| Q1 2016 | $355,000 | +5.0% | 3,758 | 0.0% | 0.00% | 0.0% |
| Q4 2015 | $338,000 | +19.9% | 3,758 | +23.3% | 0.00% | 0.0% |
| Q3 2015 | $282,000 | -85.4% | 3,047 | -84.4% | 0.00% | -85.7% |
| Q2 2015 | $1,925,000 | -31.4% | 19,574 | -30.2% | 0.01% | -30.0% |
| Q1 2015 | $2,805,000 | -34.9% | 28,047 | -39.7% | 0.01% | -28.6% |
| Q4 2014 | $4,306,000 | – | 46,547 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $13,206,000 | 5.33% |
| Montanaro Asset Management Ltd | 101,950 | $28,954,000 | 4.43% |
| Jackson Square Partners, LLC | 521,991 | $148,245,000 | 3.89% |
| Sandhill Capital Partners LLC | 119,671 | $33,987,000 | 3.88% |
| STONE RUN CAPITAL, LLC | 22,055 | $6,264,000 | 3.38% |
| Ownership Capital B.V. | 610,466 | $173,372,000 | 3.35% |
| Brown Capital Management | 823,303 | $233,818,000 | 3.28% |
| DF DENT & CO INC | 671,348 | $190,663,000 | 2.94% |
| Westwind Capital | 27,931 | $7,932,000 | 2.78% |
| MAIRS & POWER INC | 673,620 | $191,308,000 | 2.41% |